{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:25:16Z","timestamp":1794029116553,"version":"4.8.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515013158"],"award-info":[{"award-number":["2024A1515013158"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>FMS-like tyrosine kinase 3\u2013internal tandem duplication (FLT3\/ITD) is a common driver mutation that presents with a high leukemic burden and its impact on metabolic homeostasis remains to be further investigated. Here, we revealed that the oncogenic activation of FLT3\/ITD induced upregulation of target genes of sterol regulatory element-binding proteins (SREBPs) in vivo and in acute myeloid leukemia patients. Quizartinib is a second-generation FLT3 inhibitor that selectively inhibits the activating FLT3 mutations. We demonstrated the critical role of SREBP1 degradation in conferring the response of FLT3\/ITD cells to quizartinib. Mechanistically, quizartinib facilitated degradation of the precursor form of SREBP1 via the FLT3\/AKT\/GSK3 axis and reduced protein levels of its target gene fatty acid synthase (FASN). Lipidomics analysis by Liquid Chromatography Mass Spectrometry (LC-MS) demonstrated that inhibition of FLT3 altered global levels of phospholipids including reduction of cardiolipin, leading to subsequent loss of mitochondrial membrane potential. Pharmacological inhibition of SREBP1 or FASN sensitized FLT3\/ITD leukemia cells to quizartinib. Quizartinib combined with SREBP inhibitor fatostatin or FASN inhibitor orlistat provided substantial therapeutic benefit over monotherapies in the murine FLT3\/ITD leukemia model. Our results indicated the mechanistic link between FLT3\/ITD and SREBP degradation and suggested the combination therapy via targeting FLT3\/SREBP\/FASN axis.<\/jats:p>","DOI":"10.1038\/s41419-025-07661-6","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T05:57:58Z","timestamp":1745301478000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Targeting oncogenic activation of FLT3\/SREBP\/FASN promotes the therapeutic effect of quizartinib involving disruption of mitochondrial phospholipids"],"prefix":"10.1038","volume":"16","author":[{"given":"Feng","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-8243","authenticated-orcid":false,"given":"Shijun","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2152-9152","authenticated-orcid":false,"given":"Peng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3089-9945","authenticated-orcid":false,"given":"Yumin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"7661_CR1","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/nature11016","volume":"485","author":"CC Smith","year":"2012","unstructured":"Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012;485:260\u20133.","journal-title":"Nature"},{"key":"7661_CR2","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1038\/leu.2017.45","volume":"31","author":"HQ Ju","year":"2017","unstructured":"Ju HQ, Zhan G, Huang A, Sun Y, Wen S, Yang J, et al. ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition. Leukemia. 2017;31:2143\u201350.","journal-title":"Leukemia"},{"key":"7661_CR3","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1182\/blood-2017-12-820035","volume":"131","author":"P Gallipoli","year":"2018","unstructured":"Gallipoli P, Giotopoulos G, Tzelepis K, Costa ASH, Vohra S, Medina-Perez P, et al. Glutaminolysis is a metabolic dependency in FLT3(ITD) acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. Blood. 2018;131:1639\u201353.","journal-title":"Blood"},{"key":"7661_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.exphem.2017.09.007","volume":"58","author":"MA Gregory","year":"2018","unstructured":"Gregory MA, Nemkov T, Reisz JA, Zaberezhnyy V, Hansen KC, D\u2019Alessandro A, et al. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia. Exp Hematol. 2018;58:52\u20138.","journal-title":"Exp Hematol"},{"key":"7661_CR5","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1158\/2159-8290.CD-20-0738","volume":"11","author":"S Bjelosevic","year":"2021","unstructured":"Bjelosevic S, Gruber E, Newbold A, Shembrey C, Devlin JR, Hogg SJ, et al. Serine biosynthesis is a metabolic vulnerability in FLT3-ITD-driven acute myeloid leukemia. Cancer Discov. 2021;11:1582\u201399.","journal-title":"Cancer Discov"},{"key":"7661_CR6","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/nrendo.2017.91","volume":"13","author":"H Shimano","year":"2017","unstructured":"Shimano H, Sato R. SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology. Nat Rev Endocrinol. 2017;13:710\u201330.","journal-title":"Nat Rev Endocrinol"},{"key":"7661_CR7","doi-asserted-by":"publisher","first-page":"e25015","DOI":"10.7554\/eLife.25015","volume":"6","author":"S Rong","year":"2017","unstructured":"Rong S, Cortes VA, Rashid S, Anderson NN, McDonald JG, Liang G, et al. Expression of SREBP-1c requires SREBP-2-mediated generation of a sterol ligand for LXR in livers of mice. Elife. 2017;6:e25015.","journal-title":"Elife"},{"key":"7661_CR8","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cmet.2012.09.002","volume":"16","author":"W Shao","year":"2012","unstructured":"Shao W, Espenshade PJ. Expanding roles for SREBP in metabolism. Cell Metab. 2012;16:414\u20139.","journal-title":"Cell Metab"},{"key":"7661_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2013.05.017","volume":"18","author":"E Currie","year":"2013","unstructured":"Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18:153\u201361.","journal-title":"Cell Metab"},{"key":"7661_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100905","volume":"52","author":"JC Zhao","year":"2022","unstructured":"Zhao JC, Agarwal S, Ahmad H, Amin K, Bewersdorf JP, Zeidan AM. A review of FLT3 inhibitors in acute myeloid leukemia. Blood Rev. 2022;52:100905.","journal-title":"Blood Rev"},{"key":"7661_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107059","volume":"200","author":"R Roskoski Jr","year":"2024","unstructured":"Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update. Pharmacol Res. 2024;200:107059.","journal-title":"Pharmacol Res"},{"key":"7661_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.critrevonc.2019.06.011","volume":"141","author":"TM Weis","year":"2019","unstructured":"Weis TM, Marini BL, Bixby DL, Perissinotti AJ. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. Crit Rev Oncol Hematol. 2019;141:125\u201338.","journal-title":"Crit Rev Oncol Hematol"},{"key":"7661_CR13","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.chembiol.2009.07.007","volume":"16","author":"S Kamisuki","year":"2009","unstructured":"Kamisuki S, Mao Q, Abu-Elheiga L, Gu Z, Kugimiya A, Kwon Y, et al. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem Biol. 2009;16:882\u201392.","journal-title":"Chem Biol"},{"key":"7661_CR14","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1158\/0008-5472.CAN-03-3645","volume":"64","author":"SJ Kridel","year":"2004","unstructured":"Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004;64:2070\u20135.","journal-title":"Cancer Res"},{"key":"7661_CR15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ccr.2007.08.031","volume":"12","author":"BH Lee","year":"2007","unstructured":"Lee BH, Tothova Z, Levine RL, Anderson K, Buza-Vidas N, Cullen DE, et al. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell. 2007;12:367\u201380.","journal-title":"Cancer Cell"},{"key":"7661_CR16","doi-asserted-by":"publisher","first-page":"7808","DOI":"10.1021\/jm9007533","volume":"52","author":"Q Chao","year":"2009","unstructured":"Chao Q, Sprankle KG, Grotzfeld RM, Lai AG, Carter TA, Velasco AM, et al. Identification of N-(5-tert-butyl-isoxazol-3-yl)-N\u2019-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1, 3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. J Med Chem. 2009;52:7808\u201316.","journal-title":"J Med Chem"},{"key":"7661_CR17","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","volume":"114","author":"PP Zarrinkar","year":"2009","unstructured":"Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009;114:2984\u201392.","journal-title":"Blood"},{"key":"7661_CR18","doi-asserted-by":"publisher","first-page":"e79940","DOI":"10.7554\/eLife.79940","volume":"11","author":"HJ Park","year":"2022","unstructured":"Park HJ, Gregory MA, Zaberezhnyy V, Goodspeed A, Jordan CT, Kieft JS, et al. Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM\/mTOR pathway regulating oxidative phosphorylation. Elife. 2022;11:e79940.","journal-title":"Elife"},{"key":"7661_CR19","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1074\/jbc.M116.767277","volume":"292","author":"YC Kuan","year":"2017","unstructured":"Kuan YC, Hashidume T, Shibata T, Uchida K, Shimizu M, Inoue J, et al. Heat shock protein 90 modulates lipid homeostasis by regulating the stability and function of sterol regulatory element-binding protein (SREBP) and SREBP cleavage-activating protein. J Biol Chem. 2017;292:3016\u201328.","journal-title":"J Biol Chem"},{"key":"7661_CR20","doi-asserted-by":"publisher","first-page":"36431","DOI":"10.1074\/jbc.M105200200","volume":"276","author":"Y Hirano","year":"2001","unstructured":"Hirano Y, Yoshida M, Shimizu M, Sato R. Direct demonstration of rapid degradation of nuclear sterol regulatory element-binding proteins by the ubiquitin-proteasome pathway. J Biol Chem. 2001;276:36431\u20137.","journal-title":"J Biol Chem"},{"key":"7661_CR21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299\u2013312.","journal-title":"Leukemia"},{"key":"7661_CR22","doi-asserted-by":"publisher","first-page":"5885","DOI":"10.1074\/jbc.M807906200","volume":"284","author":"MT Bengoechea-Alonso","year":"2009","unstructured":"Bengoechea-Alonso MT, Ericsson J. A phosphorylation cascade controls the degradation of active SREBP1. J Biol Chem. 2009;284:5885\u201395.","journal-title":"J Biol Chem"},{"key":"7661_CR23","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cmet.2005.04.010","volume":"1","author":"A Sundqvist","year":"2005","unstructured":"Sundqvist A, Bengoechea-Alonso MT, Ye X, Lukiyanchuk V, Jin J, Harper JW, et al. Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab. 2005;1:379\u201391.","journal-title":"Cell Metab"},{"key":"7661_CR24","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10863-015-9607-y","volume":"47","author":"EM Mejia","year":"2015","unstructured":"Mejia EM, Hatch GM. Erratum to: Mitochondrial phospholipids: role in mitochondrial function. J Bioenerg Biomembr. 2015;47:279\u201380.","journal-title":"J Bioenerg Biomembr"},{"key":"7661_CR25","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.stem.2019.02.020","volume":"24","author":"AK Seneviratne","year":"2019","unstructured":"Seneviratne AK, Xu M, Henao JJA, Fajardo VA, Hao Z, Voisin V, et al. The mitochondrial transacylase, tafazzin, regulates for AML stemness by modulating intracellular levels of phospholipids. Cell Stem Cell. 2019;24:621\u201336.e616.","journal-title":"Cell Stem Cell"},{"key":"7661_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10863-015-9601-4","volume":"48","author":"EM Mejia","year":"2016","unstructured":"Mejia EM, Hatch GM. Mitochondrial phospholipids: role in mitochondrial function. J Bioenerg Biomembr. 2016;48:99\u2013112.","journal-title":"J Bioenerg Biomembr"},{"key":"7661_CR27","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0163-7827(01)00010-8","volume":"40","author":"H Shimano","year":"2001","unstructured":"Shimano H. Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes. Prog Lipid Res. 2001;40:439\u201352.","journal-title":"Prog Lipid Res"},{"key":"7661_CR28","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/onc.2015.123","volume":"35","author":"S Li","year":"2016","unstructured":"Li S, Oh YT, Yue P, Khuri FR, Sun SY. Inhibition of mTOR complex 2 induces GSK3\/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells. Oncogene. 2016;35:642\u201350.","journal-title":"Oncogene"},{"key":"7661_CR29","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/j.1476-5381.2008.00085.x","volume":"156","author":"GV Rayasam","year":"2009","unstructured":"Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A. Glycogen synthase kinase 3: more than a namesake. Br J Pharm. 2009;156:885\u201398.","journal-title":"Br J Pharm"},{"key":"7661_CR30","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1158\/2159-8290.CD-22-0411","volume":"13","author":"M Sabatier","year":"2023","unstructured":"Sabatier M, Birsen R, Lauture L, Mouche S, Angelino P, Dehairs J, et al. C\/EBPalpha confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia. Cancer Discov. 2023;13:1720\u201347.","journal-title":"Cancer Discov"},{"key":"7661_CR31","doi-asserted-by":"publisher","first-page":"8182","DOI":"10.1073\/pnas.1608987113","volume":"113","author":"J Tian","year":"2016","unstructured":"Tian J, Goldstein JL, Brown MS. Insulin induction of SREBP-1c in rodent liver requires LXRalpha-C\/EBPbeta complex. Proc Natl Acad Sci USA. 2016;113:8182\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7661_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/srep00178","volume":"1","author":"JT Ayala-Sumuano","year":"2011","unstructured":"Ayala-Sumuano JT, Velez-Delvalle C, Beltran-Langarica A, Marsch-Moreno M, Cerbon-Solorzano J, Kuri-Harcuch W. Srebf1a is a key regulator of transcriptional control for adipogenesis. Sci Rep. 2011;1:178.","journal-title":"Sci Rep"},{"key":"7661_CR33","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1194\/jlr.M069583","volume":"57","author":"W Shao","year":"2016","unstructured":"Shao W, Machamer CE, Espenshade PJ. Fatostatin blocks ER exit of SCAP but inhibits cell growth in a SCAP-independent manner. J Lipid Res. 2016;57:1564\u201373.","journal-title":"J Lipid Res"},{"key":"7661_CR34","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2174\/138920106779116928","volume":"7","author":"R Lupu","year":"2006","unstructured":"Lupu R, Menendez JA. Pharmacological inhibitors of fatty acid synthase (FASN)-catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?. Curr Pharm Biotechnol. 2006;7:483\u201393.","journal-title":"Curr Pharm Biotechnol"},{"key":"7661_CR35","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/13543784.2018.1471132","volume":"27","author":"A Schcolnik-Cabrera","year":"2018","unstructured":"Schcolnik-Cabrera A, Chavez-Blanco A, Dominguez-Gomez G, Taja-Chayeb L, Morales-Barcenas R, Trejo-Becerril C, et al. Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy. Expert Opin Investig Drugs. 2018;27:475\u201389.","journal-title":"Expert Opin Investig Drugs"},{"key":"7661_CR36","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1074\/jbc.M115.702597","volume":"291","author":"MK Ritchie","year":"2016","unstructured":"Ritchie MK, Johnson LC, Clodfelter JE, Pemble CWT, Fulp BE, Furdui CM, et al. Crystal structure and substrate specificity of human thioesterase 2: insights into the molecular basis for the modulation of fatty acid synthase. J Biol Chem. 2016;291:3520\u201330.","journal-title":"J Biol Chem"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07661-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07661-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07661-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T05:57:59Z","timestamp":1745301479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07661-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7661"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07661-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"12 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This research did not use either patients or patient derived materials. Animal experiments were performed with approved ethics from the Institutional Animals Care and Use Committee of Sun Yat-sen University Cancer Center (L102022023002U).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"327"}}